Cargando…

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer

Detalles Bibliográficos
Autores principales:	Lavacchi, Daniele, Fancelli, Sara, Gatta Michelet, Marta Rita, Catalano, Martina, Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798534/ https://www.ncbi.nlm.nih.gov/pubmed/35117383 http://dx.doi.org/10.21037/tcr.2019.12.83

Ejemplares similares

¡Rebeca!
por: Gómez de la Serna, Ramón, 1888-1963
Publicado: (1974)

Rebeca : una mujer inolvidable
por: Du Maurier, Daphne, Dame, 1907-
Publicado: (1946)

Rebeca : (una mujer inolvidable) /
por: Du Maurier,Daphne, 1907-
Publicado: (1957)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Rebeca : un relato de filosofía para niños /
por: Reed, Ronald
Publicado: (1989)

Las hijas de Rebeca
por: Thomas, Dylan, 1914-1953

La clave está en Rebeca /
por: Follet, Ken
Publicado: (2010)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Una cana al aire con Rebeca /
por: Quintana Rodríguez, Benito
Publicado: (2004)

Electronic nicotine delivery systems (ENDS): not still ready to put on END
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Video conference International Masterclasses with moderators Rebeca and Alejandro
por: CERN. Geneva
Publicado: (2016)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
por: Roviello, Giandomenico, et al.
Publicado: (2020)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Bartoletti, Michele, et al.
Publicado: (2020)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Another piece in the puzzle
por: Maxey, Thomas S, et al.
Publicado: (2005)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
por: Fancelli, Sara, et al.
Publicado: (2022)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4bs6e0dsf01gg9mb2no6efn7uu